Primary effusion lymphoma: current concepts and management

@article{Arora2017PrimaryEL,
  title={Primary effusion lymphoma: current concepts and management},
  author={Nivedita Arora and Arjun Gupta and Navid Sadeghi},
  journal={Current Opinion in Pulmonary Medicine},
  year={2017},
  volume={23},
  pages={365–370}
}
Purpose of review To summarize the current epidemiology, management, and outcomes of primary effusion lymphoma (PEL) and highlight possible future research efforts. Recent findings Cyclophosphamide, doxorubicin, vincristine, prednisone-based chemotherapy regimens alone or in combination with immunomodulatory agents (e.g., lenalidomide), or proteasome inhibitors (e.g., bortezomib), or targeted therapies, are commonly used to treat PEL. Highly active antiretroviral therapy should be continued or… Expand
Lenalidomide in Combination with Arsenic Trioxide: an Effective Therapy for Primary Effusion Lymphoma
TLDR
Evidence that the combination of ATO/Lena significantly enhanced survival of PEL mice, decreased the volume of exacerbated ascites in the peritoneum, and reduced tumor infiltration in organs of treated animals is presented. Expand
Durable complete remission with combination chemotherapy and bortezomib in HIV-associated plasmablastic lymphoma
TLDR
A patient with acquired immunodeficiency syndrome who presented with rectal pain and bright red blood per rectum was diagnosed with stage IVA PBL and treated with six cycles of dose adjusted etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin plus bortezomib resulting in durable complete remission 30 months after diagnosis. Expand
Remission of an HHV8-related extracavitary primary effusion lymphoma in an HIV-positive patient during antiretroviral treatment containing dolutegravir
TLDR
The complete regression of PEL has been achieved after the immune recovery, as a consequence of ART introduction, without chemotherapy, in an HIV-infected patient, regressed after ART initiation. Expand
High-dose Therapy and Autologous Hematopoietic Cell Transplantation as Consolidation Treatment for Primary Effusion Lymphoma.
TLDR
The data have shown that consolidative auto-HCT is safe and effective and should be considered for eligible patients with PEL after demonstration of an objective response to induction chemotherapy, however, the high relapse rate remains a concern and warrants the development of new strategies to mitigate post-transplantation relapse. Expand
AIDS-Associated Malignancies.
TLDR
An overview of HIV-associated malignancies mediated by HHV-8, EBV, and HPV is presented, and the effect of HAART on the epidemiology, presentation, treatment, and outcomes of these cancers is reviewed. Expand
A rare case of primary effusion lymphoma in HIV negative patient: Diagnostic challenges and literature review
TLDR
Cytologic and immunohistochemical staining pattern of PEL should be kept in mind in the diagnostic algorithm of cytological evaluation of serosal fluid not only in HIV positive patients but also HIV‐negative elderly patients. Expand
Human Immunodeficiency Virus-Related Lymphomas
TLDR
The increasing proportion of long-term survivors of lymphoma has raised the possibility of developing certain non-AIDS-defining solid tumors, especially those related to the lifestyle and viral infections in HIV-infected patients. Expand
Human herpesvirus 8‐related primary effusion lymphoma in four HIV‐uninfected patients without organ transplantation
TLDR
This is the first authentic report of HIV‐unrelated PEL from the ethnically Chinese population and it is important for clinicians to include PEL as one of the differential diagnosis when approaching HIV‐ uninfected patients with unexplained exudative body cavity effusion. Expand
Navigating the heterogeneous landscape of pediatric Kaposi sarcoma
TLDR
The heterogeneous patterns of disease presentation and treatment response observed among the divergent clinical phenotypes of pediatric KS are summarized, additional KSHV-related malignancies are highlighted, and some of the potential biological drivers of such clinical phenomena are explored. Expand
A 32-Year-Old Man With HIV Infection, Pleural Effusions, and Lymphadenopathy.
TLDR
A 32-year-old man presented with fever, nonproductive cough, diffuse lymphadenopathy, and polyarticular pain for 2 weeks and was prescribed a course of doxycycline by his primary care physician, which did not improve his symptoms. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 73 REFERENCES
Primary effusion lymphoma in an elderly patient effectively treated by lenalidomide: case report and review of literature
TLDR
A comprehensive assessment of the treatment of primary effusion lymphoma, discussed avant-garde therapies and updated the state of preclinical research with promising clinical applications in the field, believing that this review will bridge an important gap between classical chemotherapy and modern approaches of targeted therapy. Expand
Current status of treatment for primary effusion lymphoma.
TLDR
Recently, the molecular steps in KSHV/HHV-8-driven oncogenesis have begun to be revealed, and molecular targeting therapies such as proteasome, NF-κB, cytokines and surface antigens would provide evidence for their clinical use. Expand
Primary Effusion Lymphoma: Is Dose-Adjusted-EPOCH Worthwhile Therapy?
Primary effusion lymphoma (PEL) is a rare condition, which accounts for approximately 4% of all human immunodeficiency virus (HIV)-associated non-Hodgkin lymphomas. PEL has a predilection for bodyExpand
A case of HIV-negative primary effusion lymphoma treated with bortezomib, pegylated liposomal doxorubicin, and rituximab.
TLDR
A case of an elderly HIV-negative man of Mediterranean origin who was diagnosed with primary effusion lymphoma and responded dramatically to 6 cycles of a combination of bortezomib, pegylated liposomal doxorubicin, and rituximab and remains in complete remission 2 years after diagnosis. Expand
Primary effusion lymphoma.
TLDR
The prognosis for PEL is poor, with a median survival time of around 6 months, and it is hoped that more specific therapeutic targets will be revealed as the exact molecular steps in HHV-8-driven oncogenesis are unraveled. Expand
Sustained complete remission of primary effusion lymphoma with adjunctive ganciclovir treatment in an HIV-positive patient
TLDR
The case of a 31-year-old man with AIDS and diagnosis of PEL, in whom sustained and complete remission of the tumour was achieved with adjunctive ganciclovir therapy, as demonstrated by the 2-year remission achieved in the patient. Expand
Failure to eradicate AIDS-associated primary effusion lymphoma with high-dose chemotherapy and autologous stem cell reinfusion: case report and literature review.
TLDR
This report describes what is believed to be the first patient with AIDS-associated PEL to be treated with high-dose chemotherapy and autologous stem cell reinfusion and the patient succumbed to progressive cancer. Expand
Primary effusion lymphoma: successful treatment with highly active antiretroviral therapy and rituximab
TLDR
The clinical presentation of the current patient is consistent with recent case reports that suggest that primary effusion lymphoma (PEL) may have a wider spectrum of manifestations than previously thought, with the bowel being the most common site of extra-serous involvement. Expand
Use of cidofovir for the treatment of HIV-negative human herpes virus-8-associated primary effusion lymphoma.
TLDR
A case of an elderly HIV-negative Mediterranean woman diagnosed with primary effusion lymphoma (PEL) resistant to conventional chemotherapy, who exhibited complete and sustained remission after three doses of intracavitary cidofovir. Expand
Clinical features and outcome of primary effusion lymphoma in HIV-infected patients: a single-institution study.
TLDR
PEL is a rare HIV-associated NHL type occurring as a late manifestation of HIV infection with a poor clinical outcome and a shorter overall survival compared with CBCL patients. Expand
...
1
2
3
4
5
...